{
    "id": 27001,
    "fullName": "CSTF3 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "CSTF3-BRAF results from the fusion of CSTF3 and BRAF (PMID: 28539463), and has not been biochemically characterized, however, due to the effects of other BRAF fusions that result in loss of the BRAF CR1 domain and retention of the protein kinase domain (PMID: 23890088, PMID: 12781369), is predicted to result in a gain of function. CSTF3-BRAF has been identified in melanoma (PMID: 28539463).",
            "references": [
                {
                    "id": 3413,
                    "pubMedId": 23890088,
                    "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                },
                {
                    "id": 14743,
                    "pubMedId": 12781369,
                    "title": "Raf proteins and cancer: B-Raf is identified as a mutational target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12781369"
                },
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1479,
        "geneSymbol": "CSTF3",
        "terms": [
            "CSTF3",
            "CSTF-77"
        ]
    },
    "variant": "CSTF3 - BRAF",
    "createDate": "09/18/2017",
    "updateDate": "10/11/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11961,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of a CSTF3-BRAF fusion was identified in a melanoma patient harboring BRAF V600E who developed progressive disease after treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 28539463).",
            "molecularProfile": {
                "id": 28369,
                "profileName": "CSTF3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28368,
            "profileName": "CSTF3 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28369,
            "profileName": "CSTF3 - BRAF BRAF V600E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}